Common antibiotic part of a new potential pancreatic cancer therapy

A new promising combination therapy has been discovered for the treatment of one of the most deadly and difficult cancers to manage. Scientists developed a novel combination of an experimental drug and a common antibiotic that has shown encouraging results in treating pancreatic cancer in preclinical experiments.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

Objectives Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumor entities. The identification of distinct PDAC subtypes with a similar genetic background had given a first impression that probably epigenetic alterations promote tumor cell heterogeneity. Epigenetic modifications, such as histone modifications, are reversible and therefore attractive targets for cancer therapy.
Source: Pancreatology - Category: Gastroenterology Authors: Tags: 9. Experimental pancreatic cancer I Source Type: research
RenovoRx said today that it closed a $7 million tranche in a $10 million round to fund the development of its drug-device combination product designed to deliver chemotherapy directly to tumors in patients with locally advanced pancreatic cancer. The company’s round was led by Boston Scientific (NYSE:BSX) and joined by btov Partners, Astia Angels, Golden Seeds and others. Get the full story at our sister site, Drug Delivery Business News. The post RenovoRx raises $7m for drug-device pancreatic cancer therapy appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Food & Drug Administration (FDA) Funding Roundup Oncology Pharmaceuticals Regulatory/Compliance Vascular RenovoRx Source Type: news
Conclusion: PRIT allows the specific delivery of highly cytotoxic payload to tumor site competing with the conventional directly labeled antibody conjugate but results in reduced dose to normal tissue and decreased hematotoxicity. This study confirms the clinical relevance of 225Ac-PRIT.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Preclinical Probes for Oncology II Source Type: research
Cancers, Vol. 10, Pages 142: A New Strategy to Control and Eradicate “Undruggable” Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology Cancers doi: 10.3390/cancers10050142 Authors: Robert Van Sciver Michael Lee Caroline Lee Alex Lafever Elizaveta Svyatova Kevin Kanda Amber Colliver Lauren Siewertsz van Reesema Angela Tang-Tan Vasilena Zheleva Monicah Bwayi Minglei Bian Rebecca Schmidt Lynn Matrisian Gloria Petersen Amy Tang Oncogenic K-RAS mutations are found in virtually all pancreatic cancers...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
In conclusion, we discovered that electroporation can enhance the cytotoxic effect of cisplatin in pancreatic cancer cells in vitro. This effect was evident for cells from the primary culture. The obtained results confirm the importance of primary cells models in studies on the efficacy of experimental cancer therapies. PMID: 29750170 [PubMed - in process]
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
In conclusion, the present results demonstrated that under hypoxic conditions, OBX combined with a small dose of GEM may be able to inhibit the growth, migration and invasion of pancreatic cancer cells, possibly via inhibition of EMT process. These results may provide a promising strategy for pancreatic cancer therapy. PMID: 29749486 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
ammad Pancreatic cancer is a deadly disease that is resistant to most available therapeutics. Pancreatic cancer to date has no effective drugs that could enhance the survival of patients once their disease has metastasized. There is a need for the identification of novel actionable drug targets in this unusually recalcitrant cancer. Nuclear protein transport is an important mechanism that regulates the function of several tumor suppressor proteins (TSPs) in a compartmentalization-dependent manner. High expression of the nuclear exporter chromosome maintenance region 1 (CRM1) or exportin 1 (XPO1), a common feature of se...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Authors: Buoninfante OA, Pilzecker B, Aslam MA, Zavrakidis I, van der Wiel R, van de Ven M, van den Berk PCM, Jacobs H Abstract DNA damage tolerance (DDT) enables replication to continue in the presence of a damaged template and constitutes a key step in DNA interstrand crosslink repair. In this way DDT minimizes replication stress inflicted by a wide range of endogenous and exogenous agents, and provides a critical first line defense against alkylating and platinating chemotherapeutics. Effective DDT strongly depends on damage-induced, site-specific PCNA-ubiquitination at Lysine (K) 164 by the E2/E3 complex (RAD6/...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Abstract Pancreatic adenocarcinoma has an exceedingly poor prognosis, accounting for five-year survival of less than 5%. Presently, improving the efficacy of pancreatic adenocarcinoma treatment has been the focus of medical researchers worldwide. Recently, it has been suggested that deregulation of interleukin- (IL-) 6 is caused by a key gene involved in the beginning and development of pancreatic adenocarcinoma. Herein, we investigated whether suppression of IL-6 could augment gemcitabine sensitivity in the PANC-1 cells. We found considerably higher expression of IL-6 in pancreatic adenocarcinoma tissues t...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
The authors regret that a funding source was not acknowledged in the original paper. The correct Financial Support statement can be seen below.
Source: Nuclear Medicine and Biology - Category: Nuclear Medicine Authors: Tags: Corrigendum Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Pancreas | Pancreatic Cancer | Science